| |
Benign
(n=27) |
Borderline
(n=25) |
Malignant
(n=33) |
pValue |
| Stromal Atypia |
|
• Mild
|
26 (96.3%) |
09 (36%) |
0 |
p<0.0001 |
|
• Moderate
|
01 (3.7%) |
14 (56%) |
03 (9.1%) |
|
• Marked
|
0 |
02 (8%) |
30 (90.9%) |
| Stromal Cellularity |
|
• Mild
|
20 (74.1%) |
03 (12%) |
0 |
p<0.0001 |
|
• Moderate
|
07 (25.9 %) |
19 (76%) |
04 (12.1%) |
|
• Marked
|
0 |
03 (12%) |
29 (87.9%) |
| Tumor Margins |
|
• Pushing
|
27 (100%) |
21 (84%) |
03 (9.1%) |
p<0.0001 |
|
• Infiltrative
|
00 |
04 (16%) |
30 (90.9%) |
| Mitoses (per 10 HPF) |
| Range |
1-4 |
2-18 |
5-42 |
p<0.0001 |
| Average |
2.6 ± 1 |
7.6 ± 3 |
20.5 ± 9.5 |
| Mitotic Count |
|
• 0-4 / 10HPF
|
27 (100%) |
01 (4%) |
00 |
p<0.0001 |
|
• 5-9 / 10HPF
|
00 |
18 (72%) |
03 (9.1%) |
|
• >10 /10HPF
|
00 |
06 (24%) |
30 (90.9%) |
| Sarcomatous Component |
00 |
00 |
02 (6.1%) |
p =0.199 |
| Necrosis |
00 |
01 (4%) |
05 (15.2%) |
p =0.058 |
| Additional epithelial lesions |
|
• Papilloma
|
01 |
00 |
00 |
|
|
• Usual Duct Hyperplasia
|
01 |
03 |
02 |
|
• Atypical Ductal Hyperplasia
|
00 |
01 |
00 |
|
• Duuctal carcinoma in situ
|
00 |
01 |
01 |
|
